Current and Future Role of Serogenomics in Ulcerative Colitis

Mark H. Flasar, MD, MS, Raymond K. Cross, MD, MS, and David B. Doman, MD

Dr. Flasar is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Maryland School of Medicine and a staff physician in the Gastroenterology Section of the Veterans Affairs, Maryland Health Care System, both in Baltimore, Maryland. Dr. Cross is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Maryland School of Medicine and Chief of the Gastroenterology Section of the Veterans Affairs, Maryland Health Care System, both in Baltimore, Maryland. Dr. Doman is a Clinical Professor of Medicine in the Division of Gastroenterology at George Washington University School of Medicine in Washington, DC.

Address correspondence to:
Dr. Mark H. Flasar
100 North Greene Street, Lower Level
Baltimore, MD 21201;
Tel: 410-706-3387;
Fax: 410-706-4330;
E-mail: mflasar@medicine.umaryland.edu

Abstract: Ulcerative colitis (UC), a chronic inflammatory bowel disease, occurs in genetically susceptible individuals who mount inappropriate immune responses to endoluminal antigens. Serologic and genetic markers have shown great potential for clinical application in Crohn’s disease (CD), particularly for prognostication. However, their use is not as well established in UC. The aim of this paper is to highlight the clinical relevance of these markers for diagnostics and prognostication in UC. This review identified studies that cited the use of serum and genetic biomarkers in UC when these biomarkers were used in diagnostic, prognostic, and therapeutic response prediction applications. Several serologic and genetic markers associated with UC were identified, and this review presents and summarizes these data, focusing on the biomarkers’ established and emerging diagnostic and prognostic utility. Although more established in CD, the data provided by serologic and genetic testing in UC has the potential to enhance clinical decision making.

Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory disease of the large intestine that is thought to result from a dysregulated immune response to intestinal flora in genetically susceptible individuals. Patients with UC present with a spectrum of phenotypic manifestations ranging from mild proctitis to severe pancolitis. Many patients with milder disease respond to traditional, conservative, step-up treatment approaches, while a smaller but significant subset of patients may be better served by accelerated step-up approaches or even earlier, more aggressive therapies, although the latter approach is controversial. Clinical parameters such as symptom severity or endoscopic disease assessment are, at best, inexact prognostic guides for making informed, long-term therapeutic decisions. UC serogenomic profiles hold

Keywords
Biologic markers, ulcerative colitis, serologic testing, genetic markers
the promise of patient stratification for optimal clinical management. In addition, as pharmacologic companies develop new biologic alternatives to anti–tumor necrosis factor therapy, newer-generation serogenomic profiles may serve to provide targeted pharmacologic therapeutic opportunities. This review will summarize the emerging diagnostic and prognostic utility of genetic markers for UC, as well as the utility of known serologic biomarkers.

Genetics of Ulcerative Colitis

Population-based and twin studies have long supported the notion of a genetic contribution to the development of UC. Despite early findings confirming that the major histocompatibility complex region on chromosome 6 (encompassing the human leukocyte antigen [HLA] genes) is important in determining susceptibility for UC and associations with extensive disease, significant progress in clarifying and detailing this association had been relatively limited. However, recent technologic advances have promoted rapid growth in the study of the genetics of UC.

The advent of genome-wide association studies (GWASs)—which analyze pooled DNA from numerous individuals to assess for single genetic mutations (called single-nucleotide polymorphisms [SNPs]) and associate them with various traits—has allowed researchers to identify 47 confirmed UC susceptibility loci (21 in UC alone and 26 in both UC and Crohn’s disease [CD]). Additional gene polymorphisms associated with UC are continuously being introduced, proving that the field continues to progress rapidly. Studies have revealed that interleukin-23 receptor (IL-23R) and transcription factor genes that regulate cytokine expression represent the bulk of the associations common to both CD and UC; HLA, interleukin (IL)-10 signaling, and barrier function genes represent the bulk of the susceptibility loci unique to UC. In addition to these loci having an association with the development or presence of UC, some studies have suggested that some of these loci are also linked to clinical factors.

Associations Between Genetics and Clinical Factors in Ulcerative Colitis

Several methods have been used to draw associations between genetic and clinical factors of UC. First, genome analysis of DNA extracted from tissue samples can provide clues as to whether fixed genetic information is associated with disease factors. Also, the presence of genome mutations in DNA from tissue samples—either mutations in a sequence or (once identified in a GWAS) a SNP—can be analyzed to assess for relevant associations. These methods essentially hint at what a cell, organism, or individual is capable of doing. In contrast, analysis of messenger RNA samples shows what that cell, organism, or individual is actually doing at the time of sampling, as this methodology (transcriptomics) analyzes products of transcription.

While not generalizable to all UC patients, a case-control analysis of 114 UC patients with colorectal cancer who were matched with 114 UC patients without cancer revealed several significant associations (both positive and negative) between specific HLA alleles and risk of colorectal cancer in UC patients. The HLA DRB1*0103 allele has been associated with more extensive and refractory disease, shorter time to surgery, and extraintestinal manifestations (EIMs) in UC. Interestingly, the HLA DRB1*0103 allele has also been associated with a colonic CD phenotype. The barrier function gene CDH1, which encodes the transmembrane protein E-cadherin, was independently identified in separate GWASs for both UC and colorectal cancer, suggesting a possible link between UC and colonic dysplasia/neoplasia. In addition, promoter methylation of CDH1 has been associated with dysplasia in UC patients, raising the possibility that hypermethylation might be used as a biomarker for the identification of UC patients who are at increased risk for dysplasia. However, some studies have reported less promising associations. An analysis of inflammatory bowel disease (IBD)-associated IL-23R SNPs in UC patients revealed no association with disease extent, need for colectomy, or presence of EIMs.

Despite these advances, the full clinical application of these genetic discoveries has yet to be realized. Identifying targets for the development of medical therapies is an obvious application of this new information, one that has already been met via development of therapies associated with IL-23R and IL-10. Use of genetic information to develop diagnostic tests that could diagnose IBD and/or differentiate CD from UC is another attractive application. At the 2009 American College of Gastroenterology Annual Meeting, one study presented an analysis of the peripheral blood expression levels of 10 previously identified genes in a prospective cohort of 98 irritable bowel syndrome (IBS) patients and 189 IBD patients (91 UC and 98 CD). The study authors described an optimal scoring algorithm for classification of disease as IBS or IBD; this algorithm used 7 of the 10 tested genes and achieved 89% sensitivity and 74% specificity.

The following year, this same group presented a UC/CD discrimination panel of 3 genes (MMD, CD4, and DNAJ-A1) that were identified by a proprietary analytic engine (Coperna, Exagen Diagnostics) using samples from 26 UC patients and 59 CD patients. The gene panel was then tested using peripheral blood from 192 IBD patients (97 CD and 95 UC). The authors...
reported sensitivities for UC and CD of 87% and 92%, respectively; specificities were 92% and 87%, respectively. Positive and negative predictive values for both CD and UC ranged between 88% and 91%. Both abstracts have yet to be published in full manuscript form but remain intriguing, despite their methodology limitations and the lack of validation in a low-prevalence cohort. The 2 genetic testing panels are currently commercially available and have been marketed as the first genomic tests for IBD, IBS, and UC/CD.

A more recent study used a gene chip to determine the serologic gene expression profiles of 21 UC patients, 24 CD patients, and 10 control patients. The authors used logistic regression analyses to identify a set of 4 probes (IL receptor 

A smaller study examined 95 UC patients for which patients are likely to have the most severe disease scoring system could prove useful in helping to predict colectomy. The authors concluded that a SNP-based risk score based on the 46 SNPs associated with medically refractory UC accounted for nearly half of the risk of refractory UC accounted for nearly half of the risk of medical treatment response and long-term remission were both associated with high *MDR1* expression levels in this small cohort. Interestingly, in a separate analysis of 154 steroid-refractory UC patients, specific *MDR1* SNPs were associated with higher resistance rates to rescue therapy with intravenous cyclosporine A.

Kabakchiev and colleagues examined the peripheral blood RNA expression profiles of 20 steroid-responsive hospitalized pediatric UC patients and 20 steroid-resistant hospitalized pediatric UC patients on Day 3 following initiation of intravenous corticosteroids. The researchers identified a total of 41 genes that were differentially expressed between responders and nonresponders, and they noted that matrix metallopeptidase 8 and carcinoembryonic antigen–related cell adhesion molecule 1 were both overexpressed in nonresponders. They also identified a cluster of 10 genes (from the 41 genes studied) that had a sensitivity of 80% and specificity of 80% for predicting response.

Finally, in perhaps the most compelling example of how genetic markers can be combined with currently available clinical and serologic parameters in UC patients, investigators from Munich, Germany retrospectively assessed clinical activity, perinuclear antineutrophil cytoplasmic antibody (pANCA) status, and UC-specific IL-23R variants in 90 UC patients who were treated with infliximab (Remicade, Janssen Biotech) for 14 weeks. This multivariate analysis suggested that pretreatment pANCA seronegativity and the presence of IBD risk–increasing IL-23R variants were associated with a higher rate of response to infliximab. Given that microbial seroreactivity has been associated with pattern recognition receptor genes, serologic testing is likely to be a temporary diagnostic and prognostic bridge to eventual genetic testing. During this transition period, panels that combine traditional and currently available genetic serologic testing seem to be most promising.

As the genetics contributing to the pathogenesis of UC continue to be determined at a rapid rate, the promise of using genetic testing to diagnose UC and to predict clinical course and response to therapy in UC is becoming a reality. Eventually, through a combination of clinical factors, traditional serologic tests, and serologic identification of UC-specific genetic polymorphisms,
providers will likely be able to predict which patients are at high risk for colectomy and to prescribe highly effective, well-tolerated therapies.

**Sericologic Markers in Ulcerative Colitis**

In general, serologic markers refer to distinct antibodies directed against different luminal antigens. The pattern and degree of positivity of these antibodies in individual patients are felt to represent a spectrum of immune phenotypes, which can theoretically be used to help differentiate patients based on disease type, phenotype, behavior, and prognosis. Thus, serologic markers are felt to represent an intermediary between genetic markers and the overt clinical symptoms that will eventually develop. However, concerns about the long-term stability of serologic profiles have been raised, in part from observations that seropositivity was lost in CD patients following initiation of a gluten-free diet. Also, because of limitations in the CD and UC populations studied to date and the resultant limitations of the test characteristics of the antibody panels, caution is warranted when utilizing serologic testing as a primary diagnostic tool.

**Perinuclear Antineutrophil Cytoplasmic Antibodies and Anti–Saccharomyces cerevisiae Mannan Antibodies**

The earliest and most extensively studied IBD serologic markers are anti–Saccharomyces cerevisiae mannan antibodies (ASCA) and pANCA. ASCA is an antibody against mannan residues on the cell wall of the yeast *S. cerevisiae*. ASCA is typically thought of as the CD antibody, and elevated ASCA titers have been reported to be highly specific (although poorly sensitive) for identifying CD patients. A typical pANCA is an autoantibody directed against granules on the rim of neutrophil nuclei as well as intranuclear foci. Typically thought of as the UC antibody, pANCA titers are more frequently elevated in UC patients and CD patients with a UC-like phenotype than in typical CD patients or healthy controls.

Studies have reported that pANCA-positive UC patients are more refractory to medical therapy and have a higher likelihood of requiring surgery. More recently, investigators reported that UC patients with backwash ileitis were more likely to exhibit high titers of pANCA than UC patients without backwash ileitis. The reported test characteristics of a positive pANCA result for the identification of UC vary, with sensitivities of 50–67%, specificities of 75–94%, and positive predictive values of 72–93%. Both pANCA and ASCA tests are widely available; however, it has been suggested that, while ASCA results are fairly stable across different laboratories, pANCA test characteristics can vary widely.

IBD type-unclassified (IBD-U), previously called indeterminate colitis, describes a group of patients with IBD colitis who cannot be classified as having UC or CD based on standard diagnostic testing. As this subgroup of patients represents up to 10% of patients with IBD and determination of a patient's true IBD subtype has therapeutic and prognostic implications, use of serologic testing to help clarify this gray area has been avidly pursued. Several studies suggest that the absence of ASCA in a pANCA-positive patient increases the specificity for UC while decreasing the sensitivity for UC. A meta-analysis of 60 studies combining ASCA and pANCA testing in 4,019 UC patients, 3,841 CD patients, and 3,748 control patients reported similar results in terms of the ability of testing to differentiate subtypes of UC from CD, with a sensitivity of 51% and a specificity of 94%. Interestingly, the accuracy of a pANCA-positive/ASCA-negative result in identifying UC was more pronounced in a pediatric subgroup.

More specifically addressing the question of how testing can clarify a diagnosis of IBD-U, Joosens and coauthors assessed ASCA and pANCA status in a cohort of 97 IBD-U patients who were followed prospectively. Nearly half of the overall cohort was seronegative for both antibodies at baseline; most of these patients retained the diagnosis of IBD-U on follow-up examination. Thirty-two percent of patients were clinically diagnosed with UC or CD over a mean follow-up period of nearly 10 years. Of the 26 patients who were ASCA-positive/pANCA-negative, 8 were clinically diagnosed with CD during the follow-up period, and 2 were clinically diagnosed with UC. Of the 20 patients who were ASCA-negative/pANCA-positive, 7 were clinically diagnosed with UC during the follow-up period, and 4 were clinically diagnosed with CD. Interestingly, these CD patients had a UC-like phenotype. The overall results of this study did not support using ASCA and pANCA testing to differentiate CD or UC in IBD-U patients.

Prediction of disease course is another potential application of serologic testing. Use of serologic biomarkers to predict disease course, clinical relapse, and response to therapy has undergone far more development in CD than UC, although some data are available regarding serologic biomarkers in UC (Table 1). In an analysis of predictors of early response to infliximab in UC patients, Ferrante and colleagues found that only 55% of ASCA-negative/pANCA-positive UC patients exhibited early clinical response, compared to 76% of patients without this antibody response pattern. Similarly, a more recent pediatric study found reduced response rates (29%) to infliximab in pANCA-positive UC patients. A retrospective analysis that pooled 56 left-sided UC patients from 4 separate clinical trials reported that treatment-resistant patients had a higher frequency of pANCA positivity than treatment-respon-
sive patients (90% vs 60%).\textsuperscript{45} Finally, while colectomy rates were not associated with pANCA status in a population-based, Norwegian, UC cohort of 432 patients, pANCA-positive patients had a 40% higher risk of relapse over 10 years than pANCA-negative patients.\textsuperscript{56} These findings, along with others, suggest that pANCA-negative UC patients represent a subgroup that is more likely to respond to therapy, thus setting the stage for possible use of pANCA status to select between aggressive and traditional treatment algorithms.

Studies have also assessed the utility of serologic testing to predict the development of complications following colectomy with ileal pouch–anal anastomosis (IPAA) for presumed UC or IBD-U. Early studies, which suffered from significant design heterogeneity, inconsistently associated pANCA seropositivity with the development of pouchitis following IPAA.\textsuperscript{57-61} In the first study to assess pANCA levels prior to colectomy, Fleshner and coauthors reported that pouchitis developed more frequently in patients who were pANCA-positive preoperatively.\textsuperscript{62} Further, they noted an increased risk of chronic pouchitis in patients with high pANCA titers, and they found high pANCA titers to be the only independent risk factor for the development of chronic pouchitis after IPAA for UC.\textsuperscript{62} Subsequently, serology was utilized to predict other complications following IPAA. In an attempt to identify predictors of the development of ileal CD following IPAA, serologic analysis was performed on samples from 238 consecutive patients who underwent colectomy and IPAA for a diagnosis of UC or IBD-U. Sixteen patients developed CD after a median of 14 months following IPAA, and ASCA immunoglobulin (Ig)A seropositivity was found to be an independent risk factor for the development of CD.\textsuperscript{63} A separate retrospective analysis of 34 patients with UC or IBD-U who underwent IPAA and had previously undergone ASCA/pANCA serologic testing found that ASCA-positive/pANCA-negative patients were significantly more likely than ASCA-negative/pANCA-positive patients to develop CD or pouch-associated fistulae following IPAA. No association between serologic response and pouchitis was identified.\textsuperscript{64}

### Related Biomarkers

Anti-OmpC is directed against a 35-kDa \textit{Escherichia coli} outer membrane porin and exhibits cross-reactivity with pANCA. Early research suggested a possible diagnostic role of anti-OmpC in UC patients, especially those with high pANCA titers.\textsuperscript{65} However, subsequent use of anti-OmpC in addition to pANCA and ASCA in a population of IBD and control patients suggested that the utility of anti-OmpC may be limited to increasing the sensitivity of a panel of antibodies for the detection of CD.\textsuperscript{66}

Anti-I2 is directed against a \textit{Pseudomonas fluorescens}–associated DNA sequence detectable within the mucosa of IBD patients. This finding is more frequent in CD patients, as is the presence of a detectable serologic response.\textsuperscript{67} A small pediatric study did not find I2 reactivity to be helpful in distinguishing between CD and UC, despite higher reported positivity in UC patients in this study than in adult studies.\textsuperscript{68} Unfortunately, additional testing for OmpC and I2 has shown that these antibodies have minimal incremental benefit over ASCA/pANCA in differentiating IBD-U.\textsuperscript{69} Finally, Hui and colleagues analyzed the ASCA, OmpC, and I2 serologic profiles of 28 IBD-U patients to assess the development of CD or chronic pouchitis following IPAA.\textsuperscript{70} While they did not find the individual antibodies to be predictive, they did report a significantly greater frequency of chronic pouchitis in patients with any positive antibody compared to patients with no seroreactivity (63% vs 17%).\textsuperscript{70}

---

**Table 1.** Studies Showing an Association Between Perinuclear Antineutrophil Cytoplasmic Antibody (pANCA) Serologic Status and Response to Therapy in Ulcerative Colitis Patients

<table>
<thead>
<tr>
<th>Serologic pattern</th>
<th>Year</th>
<th>Authors</th>
<th>Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>pANCA-positive</td>
<td>1996</td>
<td>Sandborn WJ, et al\textsuperscript{45}</td>
<td>Increased rates of medically refractory disease; increased colectomy risk</td>
</tr>
<tr>
<td>pANCA-positive</td>
<td>2010</td>
<td>Dubinsky MC, et al\textsuperscript{55}</td>
<td>Decreased infliximab response</td>
</tr>
<tr>
<td>pANCA-positive</td>
<td>2008</td>
<td>Hoie O, et al\textsuperscript{56}</td>
<td>Increased rates of relapse; increased risk of relapse</td>
</tr>
<tr>
<td>pANCA-positive/ASCA-negative</td>
<td>2007</td>
<td>Ferrante M, et al\textsuperscript{54}</td>
<td>Decreased early infliximab response</td>
</tr>
<tr>
<td>pANCA-negative/high IBD-risk IL-23R polymorphism</td>
<td>2010</td>
<td>Jurgens M, et al\textsuperscript{35}</td>
<td>Increased infliximab response</td>
</tr>
</tbody>
</table>

ASCA=anti–\textit{Saccharomyces cerevisiae} mannan antibodies; IBD=inflammatory bowel disease; IL-23R=interleukin-23 receptor.
Serologic response to flagellin (CBir1), which was identified in the C3H/HeJ/Bir mouse model as a dominant antigen capable of inducing colitis in mice, has been found to be significantly higher in CD patients than UC patients.\(^7\) While anti-CBir1 reactivity is more common in pANCA-positive CD patients than pANCA-positive UC patients, its utility seems greater for identifying CD patients who are at risk for complicated CD.\(^2\) However, CBir1 positivity may increase the risk for the development of acute and chronic pouchitis following IPAA in UC patients, although this risk seems to be modulated by the corresponding pANCA titers.\(^7\)

**Antiglycans**

As previously discussed, ASCA is an antiglycan antibody directed against mannan residues located on the cell surface of *S. cerevisiae*. Additional antibodies directed against sugars (glycans) on the cell surface of microbes as well as immune cells have been used to identify IBD patients; these antibodies include anti–laminaribioside carbohydrate IgG (ALCA), anti–chitobioside carbohydrate IgA (ACCA), and anti–mannobioside carbohydrate IgG (AMCA).\(^5\) While these antibodies may be useful in identifying CD patients, early studies did not find a correlation between antiglycan antibodies and UC.\(^7\) Likewise, an analysis of 40 IBD-U patients by Ferrante and coworkers revealed that an assay of g-ASCA (a second-generation ASCA), ALCA, and pANCA offered no clinically relevant improvement over traditional ASCA/pANCA testing in differentiating CD from UC.\(^7\) However, a subsequent analysis of 818 IBD patients—which used 2 newer antiglycans (anti-L and anti-C) in addition to the standard panel (ACCA, ALCA, AMCA, and pANCA)—suggested additional diagnostic utility. While the majority (72%) of UC patients did not exhibit any of the antibodies on the panel, use of anti-C and anti-L increased the test’s ability to discriminate between CD and UC, as well as between isolated colonic CD and UC, compared to testing with ASCA and pANCA alone.\(^7\)

While traditional serologic testing is more readily available and broadly studied than serologic genetic testing, the practical application of traditional serologic testing in the diagnosis, differentiation, and prediction of UC is limited by proprietary laboratory methodology, test characteristics that depend strongly on disease prevalence, and inconsistent study results. While data suggest that pANCA-positive patients may represent a group that is more resistant to therapy and has an increased risk for chronic pouchitis following IPAA, traditional serologic markers need to be combined with additional serologic or serogenomic markers in order for the full potential of prediction and personalized medicine in UC to be realized.

**Conclusion**

Although dwarfed by the advances seen in CD, the diagnostic and prognostic potential of genetic and serum biomarkers in UC is increasing. As the growth of UC genetic testing moves from infancy to adolescence, traditional serum biomarkers are primarily being used to help confirm a UC diagnosis, to distinguish between UC and CD, and to predict clinical course and response to therapy. However, there is clearly room for improvement with the addition of genetic testing or identification of other serologic markers. Multiple UC-associated genes have already been identified, some of which may provide targets for future therapeutics—a strategy that has already been utilized in the development of IL-23R antagonists. In addition, genetic markers may help to identify patients who are at risk for more severe or refractory disease, dysplasia, or colorectal cancer. Such patient identification may allow selection of patients for earlier, more aggressive therapy. Serum genetic profiles may also be used to predict response and tolerability to therapy, thus allowing healthcare providers to personalize medication choices to optimize outcomes. Finally, as pharmacologic companies develop new therapies, future UC serogenomic profiles offer the promise of targeted pharmacogenomic opportunities.

**Dr. Flasar has nothing to disclose. Dr. Cross has received grant support from Prometheus Laboratories. Dr. Doman is on the speakers’ bureau for Prometheus Laboratories.**

**References**


64. Dendrinos KG, Becker JM, Sracchi AF, Sauermann IJ, LaMorte W, Farrar FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. *J Gastrointest Surg*. 2006;10:1060-1064.